PortfoliosLab logoPortfoliosLab logo
Ironwood Pharmaceuticals, Inc. (IRWD)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US46333X1081
CUSIP
46333X108
IPO Date
Feb 3, 2010

Highlights

EPS (TTM)
$0.21
PE Ratio
16.54
PEG Ratio
0.02
Total Revenue (TTM)
$296.15M
Gross Profit (TTM)
$221.01M
EBITDA (TTM)
$121.85M
Year Range
$0.53 - $5.78
Target Price
$5.35
ROA (TTM)
6.05%
ROE (TTM)
-43.77%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Ironwood Pharmaceuticals, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Ironwood Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Ironwood Pharmaceuticals, Inc. (IRWD) has returned 4.15% so far this year and 138.78% over the past 12 months. Over the last ten years, IRWD has returned -10.96% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


Ironwood Pharmaceuticals, Inc.

1D
8.67%
1M
2.63%
YTD
4.15%
6M
167.94%
1Y
138.78%
3Y*
-30.64%
5Y*
-20.25%
10Y*
-10.96%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Feb 3, 2010, IRWD's average daily return is +0.03%, while the average monthly return is +0.59%. At this rate, your investment would double in approximately 9.8 years.

Historically, 46% of months were positive and 54% were negative. The best month was Nov 2025 with a return of +82.3%, while the worst month was Jan 2025 at -47.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, IRWD closed higher 49% of trading days. The best single day was Jun 10, 2025 with a return of +36.3%, while the worst single day was Jan 30, 2025 at -38.2%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202645.10%-30.06%2.63%4.15%
2025-47.18%-31.20%-8.70%-36.58%-35.74%19.71%6.53%72.77%-0.76%46.56%82.29%-3.71%-23.93%
202424.04%-33.54%-7.64%-11.02%-18.71%3.49%4.75%-25.92%-18.58%-4.13%-10.89%25.85%-61.28%
2023-7.02%-2.17%-6.65%-1.05%4.51%-2.21%4.23%-20.65%9.43%-6.85%10.37%15.56%-7.67%
2022-4.37%-3.50%16.91%-4.61%-6.08%2.31%-0.69%-6.03%-3.72%5.60%10.69%2.31%6.26%
2021-10.27%-9.69%21.13%-1.25%4.80%11.24%3.11%-1.28%-0.31%-2.22%-13.16%5.14%2.37%

Benchmark Metrics

Ironwood Pharmaceuticals, Inc. has an annualized alpha of -3.91%, beta of 0.97, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since February 04, 2010.

  • This stock participated in 158.67% of S&P 500 Index downside but only 73.83% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-3.91%
Beta
0.97
0.09
Upside Capture
73.83%
Downside Capture
158.67%

Return for Risk

Risk / Return Rank

IRWD ranks 79 for risk / return — better than 79% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


IRWD Risk / Return Rank: 7979
Overall Rank
IRWD Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
IRWD Sortino Ratio Rank: 8282
Sortino Ratio Rank
IRWD Omega Ratio Rank: 7777
Omega Ratio Rank
IRWD Calmar Ratio Rank: 8181
Calmar Ratio Rank
IRWD Martin Ratio Rank: 7575
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Ironwood Pharmaceuticals, Inc. (IRWD) and compare them to a chosen benchmark (S&P 500 Index).


IRWDBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

1.19

0.90

+0.30

Sortino ratio

Return per unit of downside risk

2.27

1.39

+0.88

Omega ratio

Gain probability vs. loss probability

1.27

1.21

+0.05

Calmar ratio

Return relative to maximum drawdown

2.42

1.40

+1.02

Martin ratio

Return relative to average drawdown

4.56

6.61

-2.05

Explore IRWD risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Ironwood Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Ironwood Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ironwood Pharmaceuticals, Inc. was 97.31%, occurring on May 23, 2025. The portfolio has not yet recovered.

The current Ironwood Pharmaceuticals, Inc. drawdown is 83.34%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.31%Jul 18, 20181723May 23, 2025
-58.62%Mar 26, 2013724Feb 8, 2016326May 24, 20171050
-38.48%Jun 29, 201167Oct 3, 2011358Mar 8, 2013425
-38.43%Apr 14, 201094Aug 25, 2010159Apr 12, 2011253
-32.23%Jun 23, 2017156Feb 5, 2018104Jul 5, 2018260

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ironwood Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Ironwood Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for IRWD, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, IRWD has a P/E ratio of 16.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for IRWD compared to other companies in the Drug Manufacturers - Specialty & Generic industry. IRWD currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for IRWD relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, IRWD has a P/S ratio of 1.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items